文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

GLP-1RA致胃肠动力延迟对合用药物吸收影响的PBPK分析

GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis.
PubMed 文献 · Pharmacotherapy · 2025-02-23

本研究利用Simcyp PBPK模型在1000例肥胖成人虚拟队列中模拟GLP-1RA相关胃排空延迟对阿托伐他汀、二甲双胍、美托洛尔、炔雌醇和地高辛药动学的影响,并与司美格鲁肽和利拉鲁肽临床数据比较。模型预测瑞舒伐他汀、缬沙坦和达比加群的AUC分别增加64%、90%和205%,达比加群变化最显著,提示GLP-1RA可能通过延迟胃排空引起有临床意义的药物相互作用。

要点

  • GLP-1RA虽不经代谢或转运体途径致DDI,但胃排空延迟可影响合用口服药吸收。
  • PBPK模型预测达比加群AUC增加205%,窄治疗指数药物暴露升高需警惕。
  • 瑞舒伐他汀和缬沙坦AUC分别预测增加64%和90%,提示需关注合用药物暴露变化。

核心结论

  • PBPK建模提示GLP-1RA可通过延迟胃排空影响口服药物药动学,可能导致有临床意义的DDI。
  • 达比加群等窄治疗指数抗凝药暴露变化最显著,需进一步临床验证和药物警戒。

研究设计与样本

  • 基于Certara Simcyp Simulator V23的PBPK建模研究。
  • 在1000例肥胖成人虚拟队列中模拟阿托伐他汀、二甲双胍、美托洛尔、炔雌醇和地高辛药动学。
  • GLP-1RA相关胃排空延迟基于利拉鲁肽治疗患者的胶囊内镜数据模拟,结果与司美格鲁肽和利拉鲁肽使用者临床数据比较。
  • 探索性分析基于2022年Medical Expenditure Panel Survey识别的常合用药物,包括瑞舒伐他汀和达比加群。

主要发现

  • GLP-1RA诱导的胃排空延迟使多种药物AUC增加、Tmax延长。
  • 模型预测瑞舒伐他汀AUC增加64%。
  • 模型预测缬沙坦AUC增加90%。
  • 模型预测达比加群AUC增加205%,为窄治疗指数抗凝药中变化最显著者。

临床怎么用

  • 对合用窄治疗指数口服药(如达比加群)的肥胖患者接受GLP-1RA治疗时应关注暴露升高风险。
  • 可借助PBPK工具预测GLP-1RA对合用口服药药动学的影响,辅助风险缓解。

局限性

  • 结果为PBPK模型预测,尚需进一步临床验证和药物警戒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are breakthrough medicines for obesity treatment and have rapidly gained widespread clinical application. Although GLP-1RAs are generally not associated with drug-drug interactions (DDIs) via drug metabolism or transporter pathways, their effects on reduced gastrointestinal (GI) motility could influence the pharmacokinetics of coadministered oral medications. OBJECTIVES: This study uses physiologically based pharmacokinetic (PBPK) modeling to evaluate the DDI potential of GLP-1RA-induced GI motility delays. METHODS: Using Certara's Simcyp™ Simulator V23, we modeled the pharmacokinetics of atorvastatin, metformin, metoprolol, ethinyl estradiol, and digoxin in a virtual cohort of obese adults (n = 1000). GLP-1RA-related gastric emptying delays were simulated based on capsule endoscopy data from liraglutide-treated patients. Results were compared with clinical data from semaglutide and liraglutide users. Additionally, exploratory analyses were conducted on frequently coadministered drugs identified from the 2022 Medical Expenditure Panel Survey, including rosuvastatin and dabigatran. RESULTS: GLP-1RA-induced gastric emptying delays led to increased area under the concentration-time curve (AUC) and prolonged time to maximum concentration (Tmax) for several medications. The model outputs for rosuvastatin, valsartan, and dabigatran indicate increases in AUC by 64%, 90%, and 205%, respectively. Dabigatran, a narrow therapeutic index anticoagulant, exhibited the most significant changes, raising potential concerns of higher drug exposure. CONCLUSIONS: PBPK modeling suggests that GLP-1RAs can influence the pharmacokinetics of oral medications by delaying gastric emptying, potentially leading to clinically relevant DDIs. While further clinical validation and pharmacovigilance is needed, these findings highlight the importance of PBPK tools in predicting and potentially mitigating risks associated with GLP-1RA use.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Hooper L, Liu S, Pai MP, et al. GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. 2025. PMID: 39989027. doi:10.1002/phar.70007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。